Clinical-Genetic Features Influencing Disability in Spastic Paraplegia Type 4
-
Published:2022-03-30
Issue:2
Volume:8
Page:e664
-
ISSN:2376-7839
-
Container-title:Neurology Genetics
-
language:en
-
Short-container-title:Neurol Genet
Author:
Rossi Salvatore, Rubegni Anna, Riso Vittorio, Barghigiani Melissa, Bassi Maria Teresa, Battini Roberta, Bertini EnricoORCID, Cereda CristinaORCID, Cioffi EttoreORCID, Criscuolo Chiara, Dal Fabbro Beatrice, Dato Clemente, D'Angelo Maria Grazia, Di Muzio Antonio, Diamanti Luca, Dotti Maria Teresa, Filla Alessandro, Gioiosa Valeria, Liguori Rocco, Martinuzzi Andrea, Massa Roberto, Mignarri Andrea, Moroni RossanaORCID, Musumeci Olimpia, Nicita FrancescoORCID, Orologio Ilaria, Orsi Laura, Pegoraro Elena, Petrucci Antonio, Plumari Massimo, Ricca Ivana, Rizzo Giovanni, Romano SilviaORCID, Rumore Roberto, Sampaolo Simone, Scarlato Marina, Seri Marco, Stefan Cristina, Straccia Giulia, Tessa Alessandra, Travaglini Lorena, Trovato Rosanna, Ulgheri Lucia, Vazza Giovanni, Orlacchio AntonioORCID, Silvestri Gabriella, Santorelli Filippo Maria, Melone Mariarosa Anna Beatrice, Casali Carlo
Abstract
Background and ObjectivesHereditary spastic paraplegias (HSPs) are a group of inherited rare neurologic disorders characterized by length-dependent degeneration of the corticospinal tracts and dorsal columns, whose prominent clinical feature is represented by spastic gait. Spastic paraplegia type 4 (SPG4, SPAST-HSP) is the most common form. We present both clinical and molecular findings of a large cohort of patients, with the aim of (1) defining the clinical spectrum of SPAST-HSP in Italy; (2) describing their molecular features; and (3) assessing genotype-phenotype correlations to identify features associated with worse disability.MethodsA cross-sectional retrospective study with molecular and clinical data collected in an anonymized database was performed.ResultsA total of 723 Italian patients with SPAST-HSP (58% men) from 316 families, with a median age at onset of 35 years, were included. Penetrance was 97.8%, with men showing higher Spastic Paraplegia Rating Scale (SPRS) scores (19.67 ± 12.58 vs 16.15 ± 12.61, p = 0.009). In 26.6% of patients with SPAST-HSP, we observed a complicated phenotype, mainly including intellectual disability (8%), polyneuropathy (6.7%), and cognitive decline (6.5%). Late-onset cases seemed to progress more rapidly, and patients with a longer disease course displayed a more severe neurologic disability, with higher SPATAX (3.61 ± 1.46 vs 2.71 ± 1.20, p < 0.001) and SPRS scores (22.63 ± 11.81 vs 12.40 ± 8.83, p < 0.001). Overall, 186 different variants in the SPAST gene were recorded, of which 48 were novel. Patients with SPAST-HSP harboring missense variants displayed intellectual disability (14.5% vs 4.4%, p < 0.001) more frequently, whereas patients with truncating variants presented more commonly cognitive decline (9.7% vs 2.6%, p = 0.001), cerebral atrophy (11.2% vs 3.4%, p = 0.003), lower limb spasticity (61.5% vs 44.5%), urinary symptoms (50.0% vs 31.3%, p < 0.001), and sensorimotor polyneuropathy (11.1% vs 1.1%, p < 0.001). Increasing disease duration (DD) and abnormal motor evoked potentials (MEPs) were also associated with increased likelihood of worse disability (SPATAX score>3).DiscussionThe SPAST-HSP phenotypic spectrum in Italian patients confirms a predominantly pure form of HSP with mild-to-moderate disability in 75% of cases, and slight prevalence of men, who appeared more severely affected. Early-onset cases with intellectual disability were more frequent among patients carrying missense SPAST variants, whereas patients with truncating variants showed a more complicated disease. Both longer DD and altered MEPs are associated with worse disability.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Genetics (clinical),Neurology (clinical)
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|